Intravenous Formulation of HET0016 Decreased Human Glioblastoma Growth and Implicated Survival Benefit in Rat Xenograft Models

Glioblastoma (GBM) is a hypervascular primary brain tumor with poor prognosis. HET0016 is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth. Therefore, to explore novel treatments, we have generated an improved intravenous (IV) formulation of HET0016 with HP...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Meenu, Gamage, Nipuni-Dhanesha H., Alsulami, Meshal, Shankar, Adarsh, Achyut, Bhagelu R., Angara, Kartik, Rashid, Mohammad H., Iskander, Asm, Borin, Thaiz F., Wenbo, Zhi, Ara, Roxan, Ali, Meser M., Lebedyeva, Iryna, Chwang, Wilson B., Guo, Austin, Bagher-Ebadian, Hassan, Arbab, Ali S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282583/
https://www.ncbi.nlm.nih.gov/pubmed/28139732
http://dx.doi.org/10.1038/srep41809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282583/
https://www.ncbi.nlm.nih.gov/pubmed/28139732
http://dx.doi.org/10.1038/srep41809

Ejemplares similares